Literature DB >> 30689224

Alpha spending for historical versus surveillance Poisson data with CMaxSPRT.

Ivair R Silva1, Wilson M Lopes1, Philipe Dias1, W Katherine Yih2.   

Abstract

Sequential analysis hypothesis testing is now an important tool for postmarket drug and vaccine safety surveillance. When the number of adverse events accruing in time is assumed to follow a Poisson distribution, and if the baseline Poisson rate is assessed only with uncertainty, the conditional maximized sequential probability ratio test, CMaxSPRT, is a formal solution. CMaxSPRT is based on comparing monitored data with historical matched data, and it was primarily developed under a flat signaling threshold. This paper demonstrates that CMaxSPRT can be performed under nonflat thresholds too. We pose the discussion in the light of the alpha spending approach. In addition, we offer a rule of thumb for establishing the best shape of the signaling threshold in the sense of minimizing expected time to signal and expected sample size. An example involving surveillance for adverse events after influenza vaccination is used to illustrate the method.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  clinical trials; postmarket vaccine safety surveillance; sample size; time to signal

Mesh:

Substances:

Year:  2019        PMID: 30689224      PMCID: PMC6955154          DOI: 10.1002/sim.8097

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

1.  Real-time vaccine safety surveillance for the early detection of adverse events.

Authors:  Tracy A Lieu; Martin Kulldorff; Robert L Davis; Edwin M Lewis; Eric Weintraub; Katherine Yih; Ruihua Yin; Jeffrey S Brown; Richard Platt
Journal:  Med Care       Date:  2007-10       Impact factor: 2.983

2.  An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink.

Authors:  W Katherine Yih; James D Nordin; Martin Kulldorff; Edwin Lewis; Tracy A Lieu; Ping Shi; Eric S Weintraub
Journal:  Vaccine       Date:  2009-05-30       Impact factor: 3.641

3.  A conditional maximized sequential probability ratio test for pharmacovigilance.

Authors:  Lingling Li; Martin Kulldorff
Journal:  Stat Med       Date:  2010-01-30       Impact factor: 2.373

4.  Febrile Seizures After 2010-2011 Trivalent Inactivated Influenza Vaccine.

Authors:  Alison Tse Kawai; David Martin; Martin Kulldorff; Lingling Li; David V Cole; Cheryl N McMahill-Walraven; Nandini Selvam; Mano S Selvan; Grace M Lee
Journal:  Pediatrics       Date:  2015-09-14       Impact factor: 7.124

5.  Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures.

Authors:  Nicola P Klein; Bruce Fireman; W Katherine Yih; Edwin Lewis; Martin Kulldorff; Paula Ray; Roger Baxter; Simon Hambidge; James Nordin; Allison Naleway; Edward A Belongia; Tracy Lieu; James Baggs; Eric Weintraub
Journal:  Pediatrics       Date:  2010-06-29       Impact factor: 7.124

6.  Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance.

Authors:  I R Silva; M Kulldorff
Journal:  Biometrics       Date:  2015-05-22       Impact factor: 2.571

7.  Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine.

Authors:  Edward A Belongia; Stephanie A Irving; Irene M Shui; Martin Kulldorff; Edwin Lewis; Ruihua Yin; Tracy A Lieu; Eric Weintraub; W Katherine Yih; Rong Li; James Baggs
Journal:  Pediatr Infect Dis J       Date:  2010-01       Impact factor: 2.129

8.  Type I Error Probability Spending for Post-Market Drug and Vaccine Safety Surveillance With Poisson Data.

Authors:  Ivair R Silva
Journal:  Methodol Comput Appl Probab       Date:  2017-08-03       Impact factor: 1.147

Review 9.  Near real-time vaccine safety surveillance using electronic health records-a systematic review of the application of statistical methods.

Authors:  Andreia Leite; Nick J Andrews; Sara L Thomas
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-01-28       Impact factor: 2.890

10.  Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System.

Authors:  Weiling Katherine Yih; Martin Kulldorff; Sukhminder K Sandhu; Lauren Zichittella; Judith C Maro; David V Cole; Robert Jin; Alison Tse Kawai; Meghan A Baker; Chunfu Liu; Cheryl N McMahill-Walraven; Mano S Selvan; Richard Platt; Michael D Nguyen; Grace M Lee
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-11-17       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.